COLL News and Press, Collegium Pharmaceutical Inc. From 06/16/21

STOUGHTON, Mass., June 16, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced a publication titled, “Nonmedical Use of Xtampza ® ER and O...

Among all of the overwhelming and depressing statistics associated with the coronavirus pandemic, here's one number that has sometimes been overlooked: 81,003 people in the U.S. died from drug overdoses in the 12-month period that ended in June 2020. That was a 20% year-over-year increase t...

Collegium Pharmaceutical, Inc. (COLL) Q1 2021 Earnings Conference Call May 06, 2021 4:30 PM ET Company Participants Alex Dasalla - Head of Investor Relations Joe Ciaffoni - President & Chief Executive Officer Paul Brannelly - Executive Vice President & Chief Financial Officer Scott Dr...

Image source: The Motley Fool. Collegium Pharmaceutical Inc (NASDAQ: COLL) Q1 2021 Earnings Call May 6, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Collegium Pharmaceutical Inc (COLL) Q1 2021 Earnings Call Trans...

Collegium Pharmaceutical (COLL): Q1 GAAP EPS of $0.41 beats by $0.11.Revenue of $87.72M (+14.7% Y/Y) beats by $6.09M.Press Release For further details see: Collegium Pharmaceutical EPS beats by $0.11, beats on revenue

– Net Income of $15.7 Million and Adjusted EBITDA of $45.3 Million in the First Quarter of 2021 – – Nucynta ® Franchise and Adjusted EBITDA 2021 Guidance Range Raised – – Colleen Tupper Appointed as Next CFO; Paul B...

STOUGHTON, Mass., April 15, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Thursday, May 6, 2021 at 4:30 p.m. Eastern Time. The Company will discuss its financial results and p...

It has been one year since the markets bottomed in March of 2020 due to COVID. Markets have rebounded beyond most investors’ expectations, with growth and tech stealing much of the spotlight. The “rotation into value” narrative has recently gained some tractio...

Despite the COVID -19 pandemic, Collegium Pharmaceutical had an impressive 2020. The company recorded a full year of profitability and commercial progress. Collegium is off to a good start in 2021, with the company reporting Xtampza ER's quarter-to-date total script volume being up 13...

Collegium Pharmaceutical, Inc. (COLL) Q4 2020 Earnings Conference Call February 25, 2021 4:30 PM ET Company Participants Alex Dasalla - Head of Investor Relations Joe Ciaffoni - Chief Executive Officer Paul Brannelly - Chief Financial Officer Scott Dreyer - Chief Commercial Officer Conference...